Drug Profile
Research programme: SLC13A5 protein inhibitors - Eternygen/Evotec SE
Alternative Names: INDY inhibitor - Evotec SE/Eternygen; NaCT inhibitors - Eternygen/Evotec SELatest Information Update: 19 Jan 2024
Price :
$50
*
At a glance
- Originator Eternygen; Evotec AG
- Developer Eternygen; Evotec SE
- Class Small molecules
- Mechanism of Action SLC13A5 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Metabolic disorders
Most Recent Events
- 19 Jan 2024 Research and development is ongoing in Metabolic-disorders in Germany
- 28 Aug 2021 No recent reports of development identified for research development in Metabolic-disorders in Germany
- 29 Jul 2019 Research development in Metabolic disorders is ongoing in Germany (Evotec pipeline, July 2019)